山西医科大学学报2018，Vol.49Issue(2)：152-156,5.DOI:10.13753/j.issn.1007-6611.2018.02.011
阿卡波糖和瑞格列奈治疗2型糖尿病的药物经济学评价
Pharmacoeconomic evaluation of acarbose and repaglinide in treating type 2 diabetes
摘要
Abstract
Objective To evaluate the curative effect and economical efficiency of acarbose and repaglinide in treating type 2 diabetes for providing the basis for decision makers pricing and patients'selection of drugs. Methods The study was a retrospective study. After the literature analysis,the data were collected through field research,and then the samples were divided into acarbose group and repaglinide group according to different medication. Cost effectiveness analysis(CEA)and incremental cost-effectiveness analysis were used to evaluate the pharmacoeconomics. Results Baseline information was not statistically significant between two groups(P >0.05). After treatment,the levels of FPG,2hPBG and HbA1c of patients were significantly decreased in two groups(P<0.05),and the total effective rate in repaglinide group was higher. The total cost was statistically lower in repaglinide group than in acarbose group (P<0.05). The cost-effectiveness ratio in acarbose group was significantly higher than that in repaglinide group(P<0.05). Con-clusion Acarbose and repaglinide are both effective in the improvement of FPG,2hPBG and HbA1c,and the repaglinide has better effect and costs less. In terms of the perspective of pharmacoeconomics,repaglinide is more economical in the treatment of type 2 dia-betes.关键词
阿卡波糖/瑞格列奈/2型糖尿病/药物经济学Key words
acarbose/repaglinide/type 2 diabetes/pharmaceutical economics分类
医药卫生引用本文复制引用
殷丽丽,段利忠,刘航宇,孙巧巧,康茜茜,卢奇..阿卡波糖和瑞格列奈治疗2型糖尿病的药物经济学评价[J].山西医科大学学报,2018,49(2):152-156,5.基金项目
国家社会科学基金资助项目(16BJY126) （16BJY126）
卫生计生健康智库联盟2017年课题 （）
